Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts

Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AM (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Journal of Clinical Oncology American Society of Clinical Oncology

Book Volume: 38

Pages Range: 2543-2551

Journal Issue: 22

DOI: 10.1200/JCO.19.03034

Abstract

PURPOSE: Three new therapies have been approved recently for the adjuvant treatment of stage III melanoma, substantially reducing the risk of tumor recurrences. This study evaluates 3 independent data sets to clarify the survival probabilities of patients with stage III melanoma. PATIENTS AND METHODS: The Central Malignant Melanoma Registry (CMMR) evaluated 1,553 patients with a primary diagnosis of stage III melanoma from 2000 to 2012. Studies from the European Organisation for Research and Treatment of Cancer (EORTC), of 573 patients in the observation arm of the 18991 study and 445 patients in the placebo arm of the 18071 study, were evaluated as reference cohorts. The survival outcomes were compared with the published American Joint Committee on Cancer version 8 (AJCCv8) stage III survival data. RESULTS: For the CMMR stage III cohort versus the AJCCv8 cohort, the melanoma-specific survival (MSS) rates at 5 years were 67% versus 77%, and at 10 years were 56% versus 69%, respectively. For stage IIIA, the MSS rates at 5 years were 80% versus 93%, and at 10 years were 71% versus 88%; for stage IIIB, the MSS rates at 5 years were 75% versus 83%, and at 10 years were 61% versus 77%. The MSS rates of the EORTC studies either overlapped with or were lower than, the CMMR data. CONCLUSION: The MSS rates in the CMMR and EORTC cohorts over the entire stage III are less favorable than those published in AJCCv8. This is particularly true for substages IIIA and IIIB.

Authors with CRIS profile

Lucie Heinzerling Department of Dermatology

Involved external institutions

Eberhard Karls Universität Tübingen DE Germany (DE) European Organisation for Research and Treatment of Cancer (EORTC) BE Belgium (BE) Universitätsklinikum Würzburg DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Universitätsklinikum Essen DE Germany (DE) Johannes Wesling Klinikum Minden DE Germany (DE) Universitätsklinikum Halle (Saale) DE Germany (DE) Universitätsklinikum Magdeburg A.ö.R. DE Germany (DE) Universitätsklinikum Mannheim DE Germany (DE) Krankenhaus Dresden-Friedrichstadt, Städtisches Klinikum DE Germany (DE) Städtisches Klinikum Dessau DE Germany (DE) Policlinico San Matteo Pavia Fondazione IRCCS IT Italy (IT) Princess Máxima Center NL Netherlands (NL)

How to cite

APA:

Garbe, C., Keim, U., Suciu, S., Amaral, T., Eigentler, T.K., Gesierich, A.,... Eggermont, A.M. (2020). Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. Journal of Clinical Oncology, 38(22), 2543-2551. https://doi.org/10.1200/JCO.19.03034

MLA:

Garbe, Claus, et al. "Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts." Journal of Clinical Oncology 38.22 (2020): 2543-2551.

BibTeX: Download